ENLIVEN THERAPEUTICS, INC. Operating Lease Liability
ENLIVEN THERAPEUTICS, INC. (ELVN) had Operating Lease Liability of $1.51 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-05
- 2026-06-30: Operating Lease, Liability $1.51M.
- 2026-03-31: Operating Lease, Liability $302.00K.
- 2025-12-31: Operating Lease, Liability $399.00K.
- 2025-09-30: Operating Lease, Liability $490.00K.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $1.51M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $302.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $399.00K 10-K · filed 2026-03-03 |
| 2025-09-30 | $490.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $580.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $667.00K 10-Q · filed 2025-05-14 |
| 2025-01-31 | $700.00K 10-Q · filed 2026-08-05 |
| 2024-09-30 | $85.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $169.00K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $252.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $335.00K 10-K · filed 2024-03-14 |
| 2023-09-30 | $413.00K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $491.00K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $568.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $644.00K 8-K · filed 2023-06-23 |
| 2022-06-30 | $445.00K 10-Q · filed 2022-08-03 |
| 2022-03-31 | $2.48M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $652.00K 10-K · filed 2022-03-15 |
| 2021-09-30 | $716.00K 10-Q · filed 2021-11-09 |
| 2021-06-30 | $781.00K 10-Q · filed 2021-08-06 |
| 2021-03-31 | $846.00K 10-Q · filed 2021-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |